DHH-B (Dihydrohonokiol-B).

DHH-B is a hydrogenated derivative of the magnolia lignans, and both it and honokiol act as positive modulators at the GABA-A receptor complex. Used together they push the same chloride channel target from closely related structures.

Magnolol and DHH-B both bind the GABA-A receptor at sites distinct from the neurotransmitter itself and increase channel opening in the presence of GABA. Whole magnolia preparations deliver them alongside one another.

Magnolia bark is the botanical source of the lignan series DHH-B belongs to, so the extract supplies the related honokiol and magnolol alongside it. Formulators pair the isolate with the bark to keep the full lignan profile.

DHH-B works at the GABA-A chloride channel while theanine raises alpha wave activity and modulates glutamate transport, so the two act at different points of the same relaxation circuit. This is long standing evening formulation practice.

Glycine opens its own inhibitory chloride channel in the brainstem and spinal cord, a separate gate from the GABA-A channel DHH-B modulates. The two lower excitability through parallel routes.

Melatonin signals circadian timing at MT1 and MT2 receptors while DHH-B works on GABA-A tone, so one sets the clock and the other lowers arousal. Neither competes with the other for a receptor.

Apigenin is a flavone that binds the benzodiazepine site of the GABA-A receptor, the same complex DHH-B modulates. Combining them stacks activity on one receptor family, so total load matters more than either alone.

Valerenic acid modulates the beta subunit of the GABA-A receptor, a different subunit interface from the classical modulator site. The effects on the same channel are additive, which is the point of the pairing and also the reason to keep doses conservative.

Magnesium sits in the NMDA receptor pore and damps excitatory signalling while DHH-B raises inhibitory tone at GABA-A. The glycine carrier also supplies an inhibitory amino acid of its own.

A positive allosteric modulator does nothing on its own; it increases the response to GABA that is already there. Supplemental GABA is poorly absorbed into the brain in adults, so the pairing is mechanistically coherent but limited by that absorption problem rather than by the receptor. Anyone stacking them should expect the modulator, not the amino acid, to be doing the work.

Glutamate decarboxylase needs pyridoxal 5-phosphate to convert glutamate into GABA, so B6 status sets the supply of the neurotransmitter that an allosteric modulator amplifies. This is settled biochemistry rather than a tested combination. It is the reason B6 turns up in most calm-support formulas.

Taurine has weak direct activity at GABA-A and glycine chloride channels, a different point of contact from an allosteric modulator that binds elsewhere on the same complex. The two therefore push the same inhibitory current by separate routes. Effect size in people is not established for either input.

Passionflower flavonoids are reported to interact with the GABA-A complex in preclinical work, so combining them with a benzodiazepine-site-independent modulator stacks two inputs on the same channel. Drowsiness is the additive effect to watch, not a benefit that has been measured for the pair. Introduce one at a time.

Lemon balm constituents are reported to slow the enzyme that breaks GABA down, which raises the pool of transmitter available. A modulator that amplifies each GABA binding event then has more to amplify. Mechanistically complementary, with drowsiness as the additive risk.

Chamomile's flavone content, apigenin in particular, is the reason it appears in evening formulas, and it acts on the same receptor complex from a different site. Stacked with a magnolia-derived modulator the sedation adds. Both inputs are preclinical in their receptor detail.

Tryptophan feeds serotonin and then melatonin synthesis, a different axis from chloride-channel modulation. Formulators pair the two to cover both sleep onset signalling and inhibitory tone. The additive endpoint is drowsiness, so evening use is the sensible slot.

5-HTP bypasses tryptophan hydroxylase and raises serotonin synthesis more directly, which is a separate mechanism from GABA-A modulation. The two are commonly stacked for evening use. Anyone taking a serotonergic medicine should regard 5-HTP as the input that carries the interaction risk, not the modulator.

Inositol supplies the phosphoinositide pool that several neurotransmitter receptors signal through, which is a step downstream of receptor binding rather than at the channel. It is used at gram-level doses for mood and calm support. The pairing is formulation logic plus mechanism, with no combination evidence cited.

Ashwagandha's reported effects run through cortisol and the hypothalamic-pituitary-adrenal axis, a slow hormonal route, while a GABA-A modulator acts within seconds at the channel. Combining a fast and a slow input is the usual reason both appear in one calm formula. The additive endpoint is subjective calm and, at higher doses, drowsiness.

Rhodiola is typically used for daytime alertness and fatigue resistance, which is the opposite direction from a sedating GABA-A modulator. Put in one product the two blunt each other rather than adding. If both are wanted, splitting them across morning and evening is the coherent design.

Caffeine blocks adenosine receptors and raises arousal, while a GABA-A positive modulator increases inhibitory current. The net effect is subtraction, and a stimulant can mask the sedation without removing it. This is the clearest anti-pairing to flag on a label.

Phosphatidylserine is reported to blunt cortisol responses to a stressor, a hormonal route entirely separate from receptor modulation. It also serves as a membrane component where lipophilic modulators partition. The pairing is mechanistic and formulation-driven, with no combination data cited.